Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation

Health Policy

Volumn 121, Issue 10, 2017, Pages 1025-1030

  Towse, Adrian ^a   Hoyle, Christopher K ^b   Goodall, Jonathan ^b   Hirsch, Mark ^b   Mestre Ferrandiz, Jorge ^a   Rex, John H ^c,d  

^a OFFICE OF HEALTH ECONOMICS   (United Kingdom)

^b AstraZeneca Pharmaceuticals ^*  (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d F2G LTD   (United Kingdom)

Author keywords

Antibiotics; Healthcare system; Healthcare associated infection; Insurance model; Market dysfunction; Multidrug resistance (MDR) bacteria; Premium price model

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BUDGET; DRUG COST; ESCHERICHIA COLI; EUROPE; FUNDING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTHCARE ASSOCIATED INFECTION; INSURANCE MODEL; INVESTMENT; KLEBSIELLA PNEUMONIAE; MULTIDRUG RESISTANCE; PREMIUM PRICE MODEL; PREVALENCE; PSEUDOMONAS AERUGINOSA; REIMBURSEMENT; RISK MANAGEMENT; UNITED STATES; BACTERIAL INFECTION; BACTERIUM; DRUG DEVELOPMENT; ECONOMICS; HEALTH CARE DELIVERY; HUMAN; LEGISLATION AND JURISPRUDENCE; RISK;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DELIVERY OF HEALTH CARE; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; RISK;

EID: 85028764978     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2017.07.011     Document Type: Article

References (40)

1. DiMasi, J.A., Grabowski, H.G., Vernon, J., R&D costs and returns by therapeutic category. Drug Information Journal 38:3 (2004), 211–223.
2. Falagas, M.E., Fragoulis, K.N., Karydis, I., A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS One, 1, 2006, e11.
3. Grabowski, H., Vernon, J., DiMasi, J.A., Returns on research and development for 1990 new drug introductions. Pharmacoeconomics 20:Suppl. 3 (2002), 11–29.
4. Projan, S.J., Why is big Pharma getting out of antibacterial drug discovery?. Current Opinion in Microbiology 6:October (5) (2003), 427–430.
5. Sharma, P., Towse, A., New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options. 2011, Office of Health Economics, London, UK.
6. Tillotson, G.S., Where does novel antibiotics R&D stand among other pharmaceutical products: an industrial perspective?. Expert Review of Anti-infective Therapy 6:5 (2008 Oct), 551–552.
7. Williams, K.J., Bax, R.P., Challenges in developing new antibacterial drugs. Current Opinion in Investigational Drugs 10:February (2) (2009), 157–163.
8. Outterson, K., Powers, J.H., Daniel, G.W., McClellan, M.B., Repairing the broken market for antibiotic innovation. Health Affairs (Millwood) 34:February (2) (2015), 277–285.
9. Rex, J.H., ND4BB: addressing the antimicrobial resistance crisis. Nature Reviews Microbiology 10:March (12) (2014), 231–232.
10. Sinha, G., BARDA to pick and choose next-generation antibiotics. Nature Biotechnology, 31(August (8)), 2013, 665.
11. Rex, J.H., Eisenstein, B.I., Alder, J., Goldberger, M., Meyer, R., Dane, A., et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. The Lancet Infectious Diseases 13:March (3) (2013), 269–275.
12. Tillotson, G.S., GAIN Act legislation: is it enough?. The Lancet Infectious Diseases 12:November (11) (2012), 823–824.
13. O'Neill, J., Securing new drugs for future generations: the pipeline for antibiotics. 2015.
14. O'Neill, J., Review on Antimirobial Resistance. Takling drug-resistant infections globally: Final report and recommendations., 2016.
15. European Centre for Disease Prevention and Contro, Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. 2013, ECDC, Stockholm.
16. European Centre for Disease Prevention and Control, Antimicrobial resistance interactive database. 2014.
17. Mestre-Ferrandiz, J., Sussex, J., Towse, A., The R&D cost of a new medicine. Office of Health Economics. 2012, Office of Health Economics, London.
18. Rex JH, 2016. Personal Communication.
19. Schwaber, M.J., Navon-Venezia, S., Kaye, K.S., Ben-Ami, R., Schwartz, D., Carmeli, Y., vClinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy 50:April (4) (2006), 1257–1262.
20. Cosgrove, S.E., Kaye, K.S., Eliopoulous, G.M., Carmeli, Y., Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Archives of Internal Medicine 162:January (2) (2002), 185–190.
21. Cosgrove, S.E., The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clinical Infectious Diseases 42:January (Suppl. 2) (2006), S82–S89.
22. Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A.K., Wertheim, H.F., Sumpradit, N., et al. Antibiotic resistance-the need for global solutions. The Lancet Infectious Diseases 13:December (12) (2013), 1057–1098.
23. Smith, R., Coast, J., The true cost of antimicrobial resistance. BMJ, 346, 2013, f1493.
24. O'Neill, J., Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. 2014.
25. Kettler, H., Towse, A., Public-private partnerships for research and development: Medicines and vaccines for diseases of poverty. 2002, Office of Health Economics, London.
26. Morel, C.M., Mossialos, E., Stoking the antibiotic pipeline. BMJ, 340, 2010, c2115.
27. Mossialos, E., Morel, C., Edwards, S., Berenson, J., Gemnmill-Toyama, M., Brogan, D., Policies and incentives for promoting innovation in antibiotic research. 2009, London School of Economics and Political Science.
28. Nathan, C., Goldberg, F.M., Outlook: the profit problem in antibiotic R&D. Nature Reviews Drug Discovery 4:November (11) (2005), 887–891.
29. Outterson, K., Samora, J.B., Keller-Cuda, K., Will longer antimicrobial patents improve global public health?. The Lancet Infectious Diseases 7:August (8) (2007), 559–566.
30. Sertkaya A, Eyraud JT, Birkenbach A, Franz C, Ackerley N, Overton V, et al., Analytical framework for examining the value of antibacterial products: Submitted to U.S. Department of Health and Human Services (HHS), Washington D.C. Task order no. HHSP23337004T. 2014.
31. Towse, A., Sharma, P., Incentives for R&D for new antimicrobial drugs. International Journal of the Economics of Business 18:2 (2011), 331–350.
32. Levine, R., Kremer, M., Albright, A., Making Markets for Vaccines. 2015, Center for Global Development, Washington DC.
33. Decision No 1082/2013/EU of The European Parliament and of The Council of 22 October 2013 on serious cross-border threats to health and repealing Decision No 2119/98/EC. 2013., European Commission, (2013).
34. Process and Design Evaluation for the Pilot Advance Market Commitment (AMC) for Pneumococcal Vaccines. Dalberg Global Development Advisors. 2013.
35. Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery 9:March (3) (2010), 203–214.
36. Payne, D.J., Gwynn, M.N., Holmes, D.J., Pompliano, D.L., Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Reviews Drug Discovery 6:January (1) (2007), 29–40.
37. Stern, S., Chorzelski, S., Franken, L., Völler, S., Rentmeister, H., Grosch, B., Breaking through the Wall; follow-up report for the German GUARD Initiative., 2017, The Boston Consulting Group & The Federal Ministry of Health.
38. Seabury, S. Sood, N. Toward a New Model for Promoting the Development of Antimicrobial Drugs. Health Affairs Blog May 18, 2017. Available at: http://healthaffairs.org/blog/2017/05/18/toward-a-new-model-for-promoting-the-development-of-antimicrobial-drugs/. (Accessed 21 June 2017).
39. Ferraro, J., Towse, A., Mestre-Ferrandiz J. Incentives for New Drugs to Tackle Anti-Microbial Resistance Research Briefing, Office of Health Economics, May 2017. Available at: https://www.ohe.org/publications/incentives-new-drugs-tackle-anti-microbial-resistance. (Accessed 21 June 2017).
40. Ardal C., Rottingen J-A., Opalska A., Van Hengel A., Larsen J. 2017, Pull Incentives for Antibacterial Drug Development: An Analysis by the Trans-Atlantic Task Force on Antimicrobial Resistance.Clinical Infectious Diseases, published on line 9 June 2017 https://doi.org/10.1093/cid/cix526.